Glenmark Pharmaceuticals share price
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Last close ₹2,166.60down ₹31.90 (1.45%)BSE ₹2,129.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,198.50.
52-week range of traded prices to 23 Oct 2026
₹1,792.60Low, 28 Oct 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹61,147 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 34.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 16.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 5.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,92,79752.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 31 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,018 Crup 6.57%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹483 Crup 60.24%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 12.0%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹11,813 Cr, differs from its quarters added, ₹12,179 Cr; the company reports a discontinued business.
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 30 Jan | Mar 2026Filed 29 May | Jun 2026Filed 31 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Net profit | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.3% | 10.3% | 0.1% | 1.4% | 10.1% | 10.3% | 8.0% | 12.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2024: days before it are of the company before the change.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 1% of 247 trading days over the last year.
LowestHighest
Its median17.9Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 83% of 1,968 trading days since Nov 2018.
LowestHighest
Its median2.4Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.12.5
At or below today's level on 60% of 1,968 trading days since Nov 2018.
LowestHighest
Its median9.9Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 1% of 2,442 trading days over the last 10 years.
LowestHighest
Its median0.34%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +38.6% | +30.0% | +6.4% | 0.2% |
| 3 years | +66.4% | +66.1% | 0.0% | 0.2% |
| 5 years | +36.0% | +7.0% | +26.7% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2025 and Mar 2026.
Mutual funds holding it
235 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 124 of the 151 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 4 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 68
- CutCut. Funds that held fewer shares than at the end of the month before.
- 83
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 74
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 11
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,34,08,183 | 3.07% | ₹3,130.4 Cr |
 Invesco India Mid Cap FundInvesco Mutual Fund | 18,64,031 | 2.76% | ₹435.2 Cr |
| Invesco India Contra FundInvesco Mutual Fund | 17,01,870 | 2.06% | ₹397.3 Cr |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 13,42,939 | 2.57% | ₹313.5 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 11,63,093 | 1.31% | ₹271.5 Cr |
 ICICI Prudential Arbitrage FundICICI Prudential Mutual Fund | 10,54,500 | 0.69% | ₹246.2 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 10,48,046 | 0.86% | ₹244.7 Cr |
 SBI Arbitrage FundSBI Mutual Fund | 9,58,875 | 0.48% | ₹223.9 Cr |
 Kotak Arbitrage FundKotak Mahindra Mutual Fund | 9,55,125 | 0.30% | ₹223.0 Cr |
| Bandhan Small Cap FundBandhan Mutual Fund | 9,22,877 | 0.60% | ₹215.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Glenmark Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹5.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 31 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 3 Oct 2025 | Interim | ₹2.50 |
| 15 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 13 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 18 Sep 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 12 Sep 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
23 Oct · Analysts
Sep 2026
21 Sep · Analysts
Glenmark Pharmaceuticals share price by year
Each calendar year to 2025.Glenmark Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,035.20 | +26.5% | 2,226.70 | 1,278.95 |
| 2024 | 1,609.10 | +88.4% | 1,818.15 | 797.20 |
| 2023 | 853.95 | +101.3% | 865.40 | 371.15 |
| 2022 | 424.15 | −19.8% | 525.25 | 352.45 |
| 2021 | 528.55 | +7.1% | 687.05 | 443.95 |
| 2020 | 493.50 | +42.0% | 535.50 | 188.10 |
| 2019 | 347.45 | −49.9% | 692.15 | 274.80 |
| 2018 | 693.05 | +16.5% | 696.75 | 500.60 |
| 2017 | 594.75 | −33.1% | 959.35 | 532.15 |
| 2016 | 888.45 | −3.6% | 965.25 | 691.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2,196.00 | 2,203.80 | 2,101.60 | 2,166.60 | 2,134.72 | 8,92,797 | 52.3% |
| 22 Oct 2026 | 2,168.00 | 2,218.80 | 2,160.30 | 2,198.50 | 2,195.90 | 5,76,619 | 55.3% |
| 21 Oct 2026 | 2,216.00 | 2,249.80 | 2,163.10 | 2,194.10 | 2,194.59 | 5,68,717 | 49.3% |
| 19 Oct 2026 | 2,230.10 | 2,269.90 | 2,200.00 | 2,210.20 | 2,227.91 | 2,85,702 | 42.3% |
| 16 Oct 2026 | 2,250.50 | 2,266.90 | 2,223.70 | 2,226.70 | 2,243.79 | 6,95,427 | 63.0% |
| 15 Oct 2026 | 2,242.00 | 2,289.50 | 2,241.20 | 2,250.50 | 2,264.34 | 4,88,525 | 49.6% |
| 14 Oct 2026 | 2,275.00 | 2,286.40 | 2,242.00 | 2,246.00 | 2,257.09 | 2,57,936 | 44.0% |
| 13 Oct 2026 | 2,278.00 | 2,289.30 | 2,253.00 | 2,265.30 | 2,266.14 | 2,59,977 | 44.7% |
| 12 Oct 2026 | 2,275.00 | 2,293.90 | 2,252.00 | 2,283.00 | 2,269.27 | 6,95,528 | 50.6% |
| 9 Oct 2026 | 2,207.00 | 2,293.00 | 2,203.00 | 2,293.00 | 2,256.99 | 4,14,339 | 34.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 22 Jun 2020 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 12 Mar 2020 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
| 28 Jan 2009 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company's board met on results that day or since the trading day before. Not adjusted for. |
| 10 Sep 2007 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is a pharmaceutical company headquartered in Mumbai, with a presence in over 80 countries. Its portfolio spans branded, generic and consumer products. It operates in India, North America, Europe, Latin America and Asia, among other regions, and has a therapeutic focus on respiratory, dermatology and oncology.
The company runs 11 manufacturing sites and six research and development centres, with more than 50 offices. In respiratory care its range covers asthma, COPD, interstitial lung disease, cough and allergies. Ryaltris is a nasal spray that combines an antihistamine and a corticosteroid for allergic rhinitis. Its biotech arm, Ichnos Glenmark Innovation, is focused on next-generation multispecific antibodies. One of these, ISB 2001, has been licensed to AbbVie.
Glenmark was incorporated in 1977. Gracias Saldanha, described as its Founder Emeritus, laid the foundation stone of the company. It went public on the Indian stock exchanges and set up a North American subsidiary, Glenmark Pharmaceuticals, Inc. It acquired Medicamenta, a Czech pharmaceutical company, and spun out its active pharmaceutical ingredients arm as Glenmark Life Sciences, in which it has since divested its 75% stake.
Glenn Saldanha is Chairman and Managing Director of the company. His mother, Blanche Saldanha, a Non-Executive Director, is a member of the promoter group of the company. A promoter is the person or group that set up a company or controls it.
- Legal name
- Glenmark Pharmaceuticals Limited
- NSE symbol
- GLENMARK
- BSE code
- 532296
- ISIN
- INE935A01035
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 2000
- Face value
- ₹1
- CIN
- L24299MH1977PLC019982
- Corporate identity number, the registrar of companies' code for it
In Nifty 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, Nifty Midcap 100